ClinicalTrials.gg
CompletedNCT00494871Updated Apr 20, 2015Results posted

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Warfarin in Atrial Fibrillation, sponsored by Bayer. Completed at 165 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-20.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,280
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Enrollment
14th of 45
1,280 · median 150
Started
2007
the only one that year
Phase 3
16 of 45
none open now
Registered
2nd of 45
by date
Lead sponsor
8 of 45
Bayer

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 14th largest by enrollment, is the only one that started in 2007, is one of 16 in phase 3, and was the 2nd registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).

Read the detailed description

Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • BAY59-7939
  • Rivaroxaban
  • Non-Valvular Atrial Fibrillation
  • Japanese Patients
  • Phase III
  • 12620
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years or older
  • Japanese male or female
  • Non- valvular atrial fibrillation documented by
  • Patients with a risk of stroke and non-CNS systemic embolism

Exclusion criteria

Exclusion Criteria:

  • Significant mitral stenosis
  • Patients in whom anticoagulants are
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,280 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (Xarelto, BAY59-7939)

    Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period

    Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Warfarin placebo

  • Active comparator
    Warfarin

    Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period

    Drug: Warfarin · Drug: Rivaroxaban placebo

Interventions

  • Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)

  • Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)

  • DrugRivaroxaban placebo

    Participants orally administered a rivaroxaban placebo tablet

  • DrugWarfarin placebo

    Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)

06

What researchers measure

Primary outcomes

  1. Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding

    Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.

    Time frame: Up to 2 days after the last dose

Secondary outcomes

  1. Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism

    This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.

    Time frame: Up to 2 days after the last dose

  2. Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death

    Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.

    Time frame: Up to 2 days after the last dose

  3. Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death

    Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.

    Time frame: Up to 2 days after the last dose

  4. Event Rate of Stroke

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).

    Time frame: Up to 2 days after the last dose

  5. Event Rate of Non-CNS Systemic Embolism

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.

    Time frame: Up to 2 days after the last dose

  6. Event Rate of Myocardial Infarction

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.

    Time frame: Up to 2 days after the last dose

  7. Event Rate of Vascular Death

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)

    Time frame: Up to 2 days after the last dose

  8. Event Rate of Stroke With Serious Residual Disability

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant's modified Rankin score was between 3 and 5, inclusive.

    Time frame: Up to 2 days after the last dose

  9. Event Rate of All-cause Death

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.

    Time frame: Up to 2 days after the last dose

  10. Event Rate of Adjudicated Major Bleeding

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.

    Time frame: Up to 2 days after the last dose

  11. Event Rate Adjudicated Non-major Clinically Relevant Bleeding

    All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.

    Time frame: Up to 2 days after the last dose

07

Results

Posted Apr 19, 2012

Participant flow

The first participant entered the study on 08 Jun 2007, and the last participant completed the study on 19 Jan 2010. The study was conducted at 167 centers in Japan. 164 study centers enrolled at least 1 participant.

Double-blind (DB) Treatment Period
Participant flow — Double-blind (DB) Treatment Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)Warfarin
Started640640
Started treatment639639
Completed480468
Not completed160172
Withdrew: Adverse event7370
Withdrew: Withdrawal by subject2635
Withdrew: Death83
Withdrew: Physician decision413
Withdrew: Lost to follow-up41
Withdrew: Protocol violation99
Withdrew: Clinical endpoint reached1828
Withdrew: Non-compliant with study medication31
Withdrew: Protocol driven decision point128
Withdrew: Site closed by investigator12
Withdrew: Site closed by sponsor11
Withdrew: Drop out before treatment start11
Follow-up (FU) Period
Participant flow — Follow-up (FU) Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)Warfarin
Started639639
Entered fu and valid for safety628630
Completed610616
Not completed2923
Withdrew: Adverse event11
Withdrew: Death1312
Withdrew: Lost to follow-up62
Withdrew: Physician decision01
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject55
Withdrew: Clinical endpoint reached32

Outcome measures

PrimaryEvent Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding

Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding18.0416.42
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Regression, Cox · p = 0.025 · Hazard ratio (hr): 1.11 · 95% CI 0.87 to 1.42
SecondaryEvent Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism

This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism1.262.61
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.49 · 95% CI 0.24 to 1.00
SecondaryEvent Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death

Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death1.832.85
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.65 · 95% CI 0.34 to 1.22
SecondaryEvent Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death

Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death2.182.97
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.74 · 95% CI 0.41 to 1.34
SecondaryEvent Rate of Stroke

All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of Stroke
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of Stroke1.152.49
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.46 · 95% CI 0.22 to 0.98
SecondaryEvent Rate of Non-CNS Systemic Embolism

All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of Non-CNS Systemic Embolism
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of Non-CNS Systemic Embolism0.110.12
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.99 · 95% CI 0.06 to 15.85
SecondaryEvent Rate of Myocardial Infarction

All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of Myocardial Infarction
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of Myocardial Infarction0.340.12
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 2.93 · 95% CI 0.30 to 28.16
SecondaryEvent Rate of Vascular Death

All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of Vascular Death
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of Vascular Death0.690.24
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 2.97 · 95% CI 0.60 to 14.70
SecondaryEvent Rate of Stroke With Serious Residual Disability

All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant's modified Rankin score was between 3 and 5, inclusive.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of Stroke With Serious Residual Disability
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of Stroke With Serious Residual Disability0.571.19
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.48 · 95% CI 0.16 to 1.40
SecondaryEvent Rate of All-cause Death

All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of All-cause Death
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of All-cause Death0.800.59
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 1.37 · 95% CI 0.43 to 4.31
SecondaryEvent Rate of Adjudicated Major Bleeding

All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate of Adjudicated Major Bleeding
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate of Adjudicated Major Bleeding3.003.59
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 0.85 · 95% CI 0.50 to 1.43
SecondaryEvent Rate Adjudicated Non-major Clinically Relevant Bleeding

All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.

Time frame:
Up to 2 days after the last dose
Reported as:
Number · Events per 100 patient-years
Event Rate Adjudicated Non-major Clinically Relevant Bleeding
Events per 100 patient-yearsRivaroxaban (Xarelto, BAY59-7939)Warfarin
Event Rate Adjudicated Non-major Clinically Relevant Bleeding15.4212.99
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Warfarin · Hazard ratio (hr): 1.20 · 95% CI 0.92 to 1.56

Adverse events

Collected over Reporting Group (RG) 1 + 2: Safety data collected start with the first dose of study drug up to 2 days after the last dose; Reporting Group (RG) 3 + 4: Safety data collected from last dose plus 2 days to end of trial.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RG1: Rivaroxaban Double-blind (DB) Period—151/639 (23.6%)474/639 (74.2%)
RG2: Warfarin DB Period—155/639 (24.3%)470/639 (73.6%)
RG3: Rivaroxaban Follow-up (FU) Period—50/628 (8%)73/628 (11.6%)
RG4: Warfarin FU Period—37/630 (5.9%)61/630 (9.7%)
Most frequent serious events
Showing 10 of 224
Most frequent serious events
EventRG1: Rivaroxaban Double-blind (DB) PeriodRG2: Warfarin DB PeriodRG3: Rivaroxaban Follow-up (FU) PeriodRG4: Warfarin FU Period
Ischaemic strokeNervous system disorders9/63918/63910/6284/630
PneumoniaInfections and infestations14/63910/6393/6283/630
Cardiac failureCardiac disorders12/63911/6393/6284/630
CataractEye disorders9/6397/6390/6280/630
Colonic polypGastrointestinal disorders5/6399/6390/6281/630
Atrial fibrillationCardiac disorders4/6392/6390/6281/630
Gastrointestinal haemorrhageGastrointestinal disorders0/6394/6390/6280/630
IleusGastrointestinal disorders0/6394/6390/6280/630
Sudden deathGeneral disorders4/6392/6393/6280/630
Spinal compression fractureInjury, poisoning and procedural complications4/6392/6390/6280/630
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRG1: Rivaroxaban Double-blind (DB) PeriodRG2: Warfarin DB PeriodRG3: Rivaroxaban Follow-up (FU) PeriodRG4: Warfarin FU Period
NasopharyngitisInfections and infestations206/639232/63916/62815/630
EpistaxisRespiratory, thoracic and mediastinal disorders102/63959/6396/6288/630
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders67/63979/6399/6286/630
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders55/63974/6393/6281/630
ContusionInjury, poisoning and procedural complications58/63956/6394/6284/630
DiarrhoeaGastrointestinal disorders57/63940/6393/6286/630
Back painMusculoskeletal and connective tissue disorders50/63956/6395/6287/630
Gingival bleedingGastrointestinal disorders54/63931/6391/6282/630
Diabetes mellitusMetabolism and nutrition disorders43/63931/6390/6281/630
EczemaSkin and subcutaneous tissue disorders37/63943/6392/6281/630

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rivaroxaban (Xarelto, BAY59-7939)WarfarinTotal
Mean71.0 ± 8.371.2 ± 7.971.1 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Xarelto, BAY59-7939)WarfarinTotal
Female110140250
Male5305001030
CL(CR) [creatinine clearance]
CL(CR) [creatinine clearance](Participants)Rivaroxaban (Xarelto, BAY59-7939)WarfarinTotal
<50 mL/min141143284
50 to <80 mL/min329329658
≥80 mL/min170168338
08

Study locations

165 sites
  • Kasugai, Aichi 487-0013, Japan
  • Nagoya, Aichi 453-8511, Japan
  • Nagoya, Aichi 454-8502, Japan
  • Nagoya, Aichi 455-8530, Japan
  • Nagoya, Aichi 457-8510, Japan
  • Nagoya, Aichi 462-0825, Japan
  • Okazaki, Aichi 444-8553, Japan
  • Goshogawara, Aomori 037-0053, Japan
  • Hirosaki, Aomori 036-8082, Japan
  • Hirosaki, Aomori 036-8545, Japan
  • Asahi, Chiba 289-2511, Japan
  • Funabashi, Chiba 274-8503, Japan
  • Imba, Chiba 270-1694, Japan
  • Matsudo, Chiba 270-2251, Japan
  • Matsudo, Chiba 271-0077, Japan
  • Yotsukaido, Chiba 284-0032, Japan
  • Imabari, Ehime 799-1592, Japan
  • Matsuyama, Ehime 790-0024, Japan
  • Matsuyama, Ehime 790-0925, Japan
  • Matsuyama, Ehime 791-8026, Japan
  • Niihama, Ehime 792-8543, Japan
  • Saijo, Ehime 793-0030, Japan
  • Toon, Ehime 791-0281, Japan
  • Chikushi-gun, Fukuoka 811-1244, Japan
  • Chikushino, Fukuoka 818-8502, Japan
  • Chikushino, Fukuoka 818-8516, Japan
  • Kasuga, Fukuoka 816-0833, Japan
  • Kasuga, Fukuoka 816-0864, Japan
  • Kitakyushu, Fukuoka 800-0057, Japan
  • Kitakyushu, Fukuoka 806-8501, Japan
  • Kurume, Fukuoka 830-8577, Japan
  • Ogori, Fukuoka 838-0141, Japan
  • Yame, Fukuoka 834-0004, Japan
  • Yame, Fukuoka 834-0006, Japan
  • Koriyama, Fukushima 963-8052, Japan
  • Ogaki, Gifu 503-8502, Japan
  • Maebashi, Gunma 371-8511, Japan
  • Mebashi, Gunma 371-0014, Japan
  • Otake, Hiroshima 739-0696, Japan
  • Asahikawa, Hokkaido 078-8214, Japan
  • Chitose, Hokkaido 066-0034, Japan
  • Hakodate, Hokkaido 040-8611, Japan
  • Muroran, Hokkaido 051-8501, Japan
  • Otaru, Hokkaido 047-8510, Japan
  • Sapporo, Hokkaido 004-0052, Japan
  • Sapporo, Hokkaido 060-0033, Japan
  • Sapporo, Hokkaido 060-0061, Japan
  • Sapporo, Hokkaido 060-8570, Japan
  • Sapporo, Hokkaido 064-0807, Japan
  • Sapporo, Hokkaido 064-8570, Japan
  • Sapporo, Hokkaido 065-0027, Japan
  • Sapporo, Hokkaido 065-0033, Japan
  • Sapporo, Hokkaido 065-8611, Japan
  • Sunagawa, Hokkaido 073-0196, Japan
  • Tomakomai, Hokkaido 053-8506, Japan
  • Kobe, Hyogo 651-0073, Japan
  • Kobe, Hyogo 651-1145, Japan
  • Kobe, Hyogo 652-0803, Japan
  • Higashiibaraki, Ibaraki 311-3193, Japan
  • Hitachi, Ibaraki 317-0077, Japan
  • Joso, Ibaraki 303-0016, Japan
  • Kasama, Ibaraki 309-1793, Japan
  • Moriya, Ibaraki 302-0112, Japan
  • Namegata, Ibaraki 311-3516, Japan
  • Toride, Ibaraki 302-0022, Japan
  • Kanazawa, Ishikawa 920-8650, Japan
  • Nomi, Ishikawa 923-1100, Japan
  • Hanamaki, Iwate 025-0075, Japan
  • Morioka, Iwate 020-0103, Japan
  • Marugame, Kagawa 763-8502, Japan
  • Takamatsu, Kagawa 760-0018, Japan
  • Izumi, Kagoshima 899-0131, Japan
  • Atsugi, Kanagawa 243-8551, Japan
  • Fujisawa, Kanagawa 251-0041, Japan
  • Fujisawa, Kanagawa 251-8550, Japan
  • Kamakura, Kanagawa 247-8533, Japan
  • Kawasaki, Kanagawa 216-8511, Japan
  • Yokohama, Kanagawa 227-0046, Japan
  • Yokohama, Kanagawa 231-8682, Japan
  • Yokohama, Kanagawa 236-0037, Japan
  • Yokohama, Kanagawa 236-0051, Japan
  • Nangoku, Kochi 783-8509, Japan
  • Uji, Kyoto 611-0042, Japan
  • Kuwana, Mie 511-0068, Japan
  • Sendai, Miyagi 980-0803, Japan
  • Sendai, Miyagi 981-3107, Japan
  • Sendai, Miyagi 983-0821, Japan
  • Sendai, Miyagi 983-8512, Japan
  • Sendai, Miyagi 983-8520, Japan
  • Komoro, Nagano 384-8588, Japan
  • Matsumoto, Nagano 390-8510, Japan
  • Suwa, Nagano 392-8510, Japan
  • Joetsu, Niigata 949-3193, Japan
  • Nagaoka, Niigata 940-8621, Japan
  • Beppu, Oita 874-0011, Japan
  • Beppu, Oita 874-0901, Japan
  • Yufu, Oita 879-5593, Japan
  • Kasaoka, Okayama 714-0043, Japan
  • Shimajiri, Okinawa 901-0493, Japan
  • Daito, Osaka 574-0074, Japan

Showing the first 100 of 165 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study -. Circ J. 2012;76(9):2104-11. doi: 10.1253/circj.cj-12-0454. Epub 2012 Jun 5. PubMed 22664783 ↗
  • Chan MY, Lin M, Lucas J, Moseley A, Thompson JW, Cyr D, Ueda H, Kajikawa M, Ortel TL, Becker RC. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost. 2012 Dec;108(6):1180-91. doi: 10.1160/TH12-05-0310. Epub 2012 Oct 10. PubMed 23052711 ↗
  • Tanahashi N, Hori M, Matsumoto M, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2013 Nov;22(8):1317-25. doi: 10.1016/j.jstrokecerebrovasdis.2012.12.010. Epub 2013 Jan 22. PubMed 23352688 ↗
  • Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013;77(3):632-8. doi: 10.1253/circj.cj-12-0899. Epub 2012 Dec 8. PubMed 23229461 ↗
  • Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M, Paolini JF, Mueck W. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 2013;28(1):59-70. doi: 10.2133/dmpk.dmpk-12-rg-034. Epub 2012 Jul 17. PubMed 22813718 ↗
  • Kaneko M, Tanigawa T, Hashizume K, Kajikawa M, Tajiri M, Mueck W. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet. 2013;28(4):321-31. doi: 10.2133/dmpk.dmpk-12-rg-109. Epub 2013 Jan 22. PubMed 23337693 ↗
  • Matsumoto M, Hori M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertens Res. 2014 May;37(5):457-62. doi: 10.1038/hr.2014.1. Epub 2014 Jan 30. PubMed 24477179 ↗
  • Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1. PubMed 24189454 ↗
  • Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. J Stroke Cerebrovasc Dis. 2014 Feb;23(2):379-83. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.021. Epub 2013 Aug 15. PubMed 23954611 ↗
  • Hori M, Kajikawa M. The J-ROCKET AF Study: a matter of ethnicity or a matter of weight? Reply. Circ J. 2013;77(10):2637. doi: 10.1253/circj.cj-13-0879. Epub 2013 Aug 1. No abstract available. PubMed 23903065 ↗
  • Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J. 2014;78(6):1349-56. doi: 10.1253/circj.cj-13-1324. Epub 2014 Apr 7. PubMed 24705469 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2007
First posted
Jul 2, 2007
Start
Jun 2007
Primary completionActual
Dec 2009
CompletionActual
Jan 2010
Results first posted
Apr 19, 2012
Last update
Apr 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00494871
Lead sponsor
Bayer
Collaborators
Janssen R&D, L.L.C.
Responsible party
Sponsor
First posted
Jul 2, 2007
Start date
Jun 2007
Primary completion
Dec 2009
Completion
Jan 2010
Results posted
Apr 19, 2012
Last update
Apr 20, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion